ArticleDiscover oncology2026
miR-27b-3p directly targets PPARG to regulate pancreatic cancer progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiR-27b-3p is dysregulated in many cancers, but its expression, clinical role, and mechanism in pancreatic cancer are not fully understood.
objectiveThis study aimed to evaluate the clinical value of miR-27b-3p in PC and its role in pancreatic cancer (PC) progression by targeting PPARG.
methodqRT-PCR was used to measure miR-27b-3p and PPARG levels in 106 paired PC tissues and adjacent non-tumor tissues, and in PC cell lines (PANC-1, SW1990, BxPC-3, AsPC-1) and HPDE cells. Kaplan-Meier and multivariate Cox analyses assessed miR-27b-3p prognostic value. CCK-8 and Transwell assays evaluated the impact of miR-27b-3p inhibition on PC cell function. Dual-luciferase reporter and Pearson correlation analyses confirmed the targeting of PPARG by miR-27b-3p. A PPARG knockdown rescue experiment verified that miR-27b-3p function depends on PPARG.
resultsmiR-27b-3p was highly expressed in PC tissues and cell lines and linked to lymph node metastasis, distant metastasis, elevated CA19-9 levels, and poor overall survival. Multivariate Cox analysis showed high miR-27b-3p expression as an independent predictor of poor prognosis. In vitro, miR-27b-3p inhibition suppressed PANC-1 cell proliferation, migration, and invasion. PPARG was a direct target of miR-27b-3p and was downregulated at both mRNA and protein levels. A negative correlation was found between miR-27b-3p and PPARG mRNA in PC tissues. PPARG knockdown reversed the effects of miR-27b-3p inhibition, confirming functional dependence.
conclusionmiR-27b-3p functions as an oncogenic miRNA in PC by targeting PPARG and may be a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.